Released Oct 29, 2026, before the open
10-Q filed Oct 29, 2026, 29 days after period end · 0000059478-26-000108
Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $24.40B | $17.60B | $11.44B | $9.50B |
| Net Income | $6.45B | $5.58B | $970.30M | -$57.40M |
Eli Lilly & Co · CIK 59478 · Engraved from SEC EDGAR
| EPS Diluted | $7.22 | $6.21 | $1.07 | -$0.06 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39%, driven by a 53% increase in volume partially offset by a 15% decrease in realized prices.¶1¶2
Q3 2026 reported EPS was $7.22, up 16%, and non-GAAP EPS was $7.48, up 7%, both including $4.57 of acquired IPR&D charges.¶3¶4
Lilly raised the midpoint of its 2026 full-year revenue guidance by $5.5 billion to $91.0 to $92.0 billion and updated non-GAAP EPS guidance to $35.00 to $36.00.¶5
Q3 2026 revenue included approximately $900 million of benefits, including $410 million of Jardiance milestones, which the filing says have no further milestones remaining.¶6¶7